EE313 Utilisation of the Cost-Saving Impact of Biosimilar Switching in Ophthalmological Diseases in the NHS: A Case-Study for a Ranibizumab Biosimilar
Jun 1, 2023, 00:00 AM
10.1016/j.jval.2023.03.614
https://www.valueinhealthjournal.com/article/S1098-3015(23)00714-3/fulltext
Section Title :
Section Order :
10095
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)00714-3&doi=10.1016/j.jval.2023.03.614